TheraCryf
plc
("TheraCryf", the "Company"
or the "Group")
Passing of Dr Sue
Foden, Chair
Alderley Park, UK - 4 November 2024:
TheraCryf plc (AIM: TCF), the clinical stage drug development
company focussing on oncology and neuropsychiatry announces with
deep sadness the sudden passing of Dr Sue Foden, the Company's
Chair.
Sue was appointed as a non-executive
director to TheraCryf plc (then Evgen Pharma plc) in 2015, becoming
Chair in September 2023. Over the past nine years, she has been a
valuable advisor and support to the leadership team and Company
overall. Her passing is a great loss to the Biotech sector in the
UK and beyond.
The Company will seek an additional
non-executive director as soon as practicable. Our thoughts are
with Sue's family during this difficult time.
Dr
Huw Jones, CEO, said:
"On behalf of the Board and all my colleagues at TheraCryf I
wanted to express our collective shock and sadness at the news of
Sue's passing. Over the years, she showed deep passion and
dedication to supporting TheraCryf and its team. Her fierce
intellect, deep scientific insights, support and guidance were very
important to me and she will be missed by us
all."
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate
Finance)
Nigel Birks / Harriet Ward (ECM)
|
+44 20 7220
0500
|
|
Vigo Consulting
Rozi
Morris
|
+44 207 7390 0230
theracryf@vigoconsulting.com
|
About TheraCryf
TheraCryf is a clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma*, neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan
indications].
Its strategy is to generate
compelling data sets to preclinical and/or clinical proof of
concept and partner its clinical programmes with mid-size to large
pharma for larger trials and commercialisation. The Company has
sourced know how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and
University of Connecticut.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol TCF. 
For further information, please
visit: www.theracryf.com
